Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-30
2011-08-30
Seaman, D M (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S119000
Reexamination Certificate
active
08008322
ABSTRACT:
The disclosure relates to substituted pyrazolo-pyridines, compositions containing them, methods for the production thereof, and to their use as medicaments, in particular, as anticancer agents.
REFERENCES:
patent: 6562811 (2003-05-01), Murata et al.
patent: 2004/0092546 (2004-05-01), Wei et al.
patent: 2004/0255397 (2004-12-01), Fessmann et al.
patent: 2007/0161626 (2007-07-01), Halley
patent: 2008/0058326 (2008-03-01), Hartung et al.
patent: 2008/0064707 (2008-03-01), Hartung et al.
patent: 2008/0182844 (2008-07-01), Bjergarde et al.
patent: WO 01/19828 (2001-03-01), None
patent: WO 02/12242 (2002-02-01), None
patent: WO 03/008405 (2003-01-01), None
patent: WO 03/045949 (2003-06-01), None
patent: WO 2004/009596 (2004-01-01), None
patent: WO 2004/076450 (2004-09-01), None
patent: WO 2004/096130 (2004-11-01), None
patent: WO 2005/009389 (2005-02-01), None
patent: 2005110410 (2005-11-01), None
patent: WO 2005/110410 (2005-11-01), None
patent: WO 2006/003276 (2006-01-01), None
patent: 2006050109 (2006-05-01), None
patent: 2006077168 (2006-07-01), None
patent: WO 2006/076442 (2006-07-01), None
patent: WO 2006/099075 (2006-09-01), None
patent: WO 2007/017577 (2007-02-01), None
patent: WO 2007/056582 (2007-05-01), None
patent: 2007144202 (2007-12-01), None
patent: 2007144204 (2007-12-01), None
Sood et al., The journal of Clinical Ivestigation, (Jan. 2010) vol. 120, No. 5, pp. 1515-1523.
Luo et al., Cancer Letters, vol. 289 (2010), pp. 127-139.
Jean-Philippe dales et al., International Journal of Oncology, vol. 22 (2003), pp. 391-397.
Lin et al., J. Clin. Invest., vol. 100(8), (1997), pp. 2072-2078.
Severine Meunier-Carpentier et al., International journal of Oncology, vol. 26, (2005), pp. 977-984.
U.S. Appl. No. 12/021,638, filed Jan. 29, 2008, Bjergarde et al.
Nagar et al, Facile Generation of Pyridopyrazoles: Synthesis of 3-amino-4-aryl-6-(p-benzoylaminophenyl)-pyrido-[2,3-d]-1-H-pyrazoles, J. Inst. Chemists (India), 2002, 74(4), pp. 129-131.
Sennitskaya et al, English Translation of: Structural Study of Indazoles, Pyrazolo[3,4-b]pyridines and Pyrazolo[3,4-b]pyrazine Using IR Spectroscopy, Chemistry of Heterocyclic Compounds, 1977, (5), pp. 662-667.
Sennitskaya et al, Structural Study of lndazoles, Pyrazolo[3,4-b]pyridines and Pyrazolo[3,4-b]pyrazine Using IR Spectroscopy, Chemistry of Heterocyclic Compounds, 1977, (5), pp. 662-667.
Zhao et al, Regulation of the Cell Cycle by Focal Adhesion Kinase, J. Cell. Biol., 1998 (143) 7, pp. 1997-2008.
Asahara et al, Tie2 Receptor Ligands, Angiopoietin-1 and Angiopoietin-2, Modulate VEGF-Induced Postnatal Neovascularization, Circ. Res., 1998 (83) pp. 233-240.
Cary et al, Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn, Journal of Cell Science, 1996 (109), pp. 1787-1794.
Chen et al, Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase, Proc. Natl. Acad. Sci. USA, 1994 (91), pp. 10148-10152.
Davis et al, Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning, Cell, 1996 (87) pp. 1161-1169.
De Marco et al, Lipophilicity-related inhibition of blood platelet aggregation by nipecotic acid anilides, Euro. Journal Pharma. Sciences, 2004 (22) pp. 153-164.
Dumont et al, Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo, Genes Dev., 1994 (8) pp. 1897-1909.
Kornberg et al, Cell Adhesion or Integrin Clustering Increases Phosphorylation of a Focal Adhesion-associated Tyrosine Kinase, J. Biol. Chem., 1992 (267) 33, pp. 23439-23442.
Lee et al, Anti-Vascular Endothelial Growth Factor Treatment Augments Tumor Radiation Response under Normoxic or Hypoxic Conditions 1, Cancer Research, 2000 (60) 19 pp. 5565-5570.
Lin et al, Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2, PNAS, 1998 (95) pp. 8829-8834.
Lin et al, Inhibition of Tumor Anglogenesis Using a Soluble Receptor Establishes a Role for Tie2 in Pathologic Vascular Growth, J. Clin. Invest., 1997 (100) 8 pp. 2072-2078.
Ling et al, Malignant Astrocytoma Cell Attachment and Migration to Various Matrix Proteins Is Differentially Sensitive to Phosphoinositide 3-OH Kinase Inhibitors, J. Cell. Biochemistry, 1999 (73), pp. 533-544.
Maisonpierre et al, Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis, Science, 1997 (277) pp. 55-60.
Maung et al, Requirement for focal adhesion kinase in tumor cell adhesion, Oncogene,1999 (18), pp. 6824-6828.
Millauer et al, Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types in Vivo, Cancer Research, 1996 (56) pp. 1615-1620.
Oktay et al, Integrin-mediated Activation of Focal Adhesion Kinase Is Required for Signaling to Jun NH2-terminal Kinase and Progression through the G1 Phase of the Cell Cycle, J. Cell. Biol., 1999 (145) 7 pp. 1461-1469.
Owens et al, Overexpression of the Focal Adhesion Kinase (p125 FAK) in Invasive Human Tumors 1, Cancer Research, 1995 (55), pp. 2752-2755.
Richardson et al, A mechanism for regulation of the adhesion-associated protein tyrosine kinase pp125 FAK, Nature, 1996 (380), pp. 538-540.
Schaller et al, Autophosphorylation of the Focal Adhesion Kinase, pp125 FAK, Directs SH2-Dependent Binding of pp60src, Mol. Cell. Biol., 1994 (14), pp. 1680-1688.
Schlaepfer et al, Focal Adhesion Kinase Overexpression Enhances Ras-dependent Integrin Signaling to ERK2/Mitogen-activated Protein Kinase through Interactions with and Activation of c-Src, J. Biol. Chem., 1997 (272) 20, pp. 13189-13195.
Schlaepfer et al, Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase, Nature, 1994 (372) 22, pp. 786-791.
Schlaepfer et al, Signaling through focal adhesion kinase, Prog. Biophy. Mol. Biol., 1999 (71), pp. 435-478.
Sieg et al, Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration, J. Cell Science, 1999 (112), pp. 2677-2691.
Strawn et.al, Flk-1 as a Target for Tumor Growth Inhibition, Cancer Research, 1996 (56) pp. 3540-3545.
Suri et al, Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis, Cell, 1996 (87) pp. 1171-1180.
Vuori et al, Induction of p130cas Signaling Complex Formation upon Integrin-Mediated Cell Adhesion: a Role for Src Family Kinases, Mol. Cell. Biol., 1996 (16) 6, pp. 2606-2613.
Wang et al, p125 focal adhesion kinase promotes malignant astrocytoma cell proliferation in vivo, J. Cell Sci., 2000 (113), pp. 4221-4230.
Weiner et al, Expression of focal adhesion kinase gene and Invasive cancer, Lancet., 1993 (342), pp. 1024-1025.
Xing et al, Direct Interaction of v-Src with the Focal Adhesion Kinase Mediated by the Src SH2 Domain, Mol. Biol. of the Cell, 1994 (5), pp. 413-421.
Xu et al, Attenuation of the Expression of the Focal Adhesion Kinase Induces Apoptosis in Tumor Cells, Cell Growth Diff., 1996 (7), pp. 413-418.
Bacque Eric
Halley Frank
Ronan Baptiste
Souaille Catherine
Tabart Michel
Aventis Pharma S.A.
Rahmani Niloofar
Scully , Scott, Murphy & Presser, P.C.
Seaman D M
LandOfFree
Substituted pyrazolopyridines, compositions containing them,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrazolopyridines, compositions containing them,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazolopyridines, compositions containing them,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2741639